SE9201584D0 - USE OF ALPHA KETOGLUTARATE - Google Patents

USE OF ALPHA KETOGLUTARATE

Info

Publication number
SE9201584D0
SE9201584D0 SE9201584A SE9201584A SE9201584D0 SE 9201584 D0 SE9201584 D0 SE 9201584D0 SE 9201584 A SE9201584 A SE 9201584A SE 9201584 A SE9201584 A SE 9201584A SE 9201584 D0 SE9201584 D0 SE 9201584D0
Authority
SE
Sweden
Prior art keywords
ketoglutarate
alpha
analogues
glutamine
medicament
Prior art date
Application number
SE9201584A
Other languages
Swedish (sv)
Inventor
E Vinnars
Original Assignee
Vinnars Erik Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vinnars Erik Ab filed Critical Vinnars Erik Ab
Priority to SE9201584A priority Critical patent/SE9201584D0/en
Publication of SE9201584D0 publication Critical patent/SE9201584D0/en
Priority to EP93910529A priority patent/EP0612245A1/en
Priority to PCT/SE1993/000426 priority patent/WO1993023027A1/en
Priority to CA002113279A priority patent/CA2113279A1/en
Priority to JP5520133A priority patent/JPH06509362A/en
Priority to AU40989/93A priority patent/AU661399B2/en
Priority to NO940190A priority patent/NO306195B1/en
Priority to US08/451,262 priority patent/US5646187A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The invention relates to the use of alpha-ketoglutarate or analogues thereof in the preparation of a medicament for treatment of critically ill patients for improving protein synthesis capacity, maintaining energy level, preserving the lean body mass and for improving the glutamine content in skeletal muscle. The medicament contains preferably alpha-ketoglutarate in such an amount, so that it provides more than 0,25g/kg body weight/day of alpha-ketoglutarate, when administered to the patient. The medicament can also comprise conventional amino acid solution and/or glutamine or analogues thereof, L-asparagine and/or acetoacetate. The invention also relates to a composition comprising conventional amino acid mixture and alpha-ketoglutarate or analogues thereof, in such an amount, so that it provides more than 0.25g/kg body weight/day of alpha-ketoglutarate, when administered to the patient, optionally with the addition of glutamine or analogues thereof, L-asparagine and/or acetoacetate, glucose and/or fat.
SE9201584A 1992-05-20 1992-05-20 USE OF ALPHA KETOGLUTARATE SE9201584D0 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
SE9201584A SE9201584D0 (en) 1992-05-20 1992-05-20 USE OF ALPHA KETOGLUTARATE
EP93910529A EP0612245A1 (en) 1992-05-20 1993-05-14 Use of alpha-ketoglutarate
PCT/SE1993/000426 WO1993023027A1 (en) 1992-05-20 1993-05-14 Use of alpha-ketoglutarate
CA002113279A CA2113279A1 (en) 1992-05-20 1993-05-14 Use of alpha-ketoglutarate
JP5520133A JPH06509362A (en) 1992-05-20 1993-05-14 Alpha-ketol glutarate usage
AU40989/93A AU661399B2 (en) 1992-05-20 1993-05-14 Use of alpha-ketoglutarate
NO940190A NO306195B1 (en) 1992-05-20 1994-01-19 Use of <alfa> ketoglutarate
US08/451,262 US5646187A (en) 1992-05-20 1995-05-26 Use of alpha-ketoglutarate

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9201584A SE9201584D0 (en) 1992-05-20 1992-05-20 USE OF ALPHA KETOGLUTARATE

Publications (1)

Publication Number Publication Date
SE9201584D0 true SE9201584D0 (en) 1992-05-20

Family

ID=20386290

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9201584A SE9201584D0 (en) 1992-05-20 1992-05-20 USE OF ALPHA KETOGLUTARATE

Country Status (7)

Country Link
EP (1) EP0612245A1 (en)
JP (1) JPH06509362A (en)
AU (1) AU661399B2 (en)
CA (1) CA2113279A1 (en)
NO (1) NO306195B1 (en)
SE (1) SE9201584D0 (en)
WO (1) WO1993023027A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9303691D0 (en) * 1993-11-09 1993-11-09 Gramineer Ab New beverage
SE9402027D0 (en) * 1994-06-10 1994-06-10 Pharmacia Ab Energy substrates
US20050085498A1 (en) * 1998-05-28 2005-04-21 Byrd Edward A. Oral formulation of lipid soluble thiamine, lipoic acid, creatine derivative, and L-arginine alpha-ketoglutarate
US20020147237A1 (en) * 2001-01-31 2002-10-10 Lars Wiklund Preservation of bodily protein
JP2004518712A (en) 2001-02-14 2004-06-24 ラート・マティアス Compositions of biochemical compounds involved in the bioenergetic metabolism of cells and uses thereof
SE0301947D0 (en) * 2003-07-01 2003-07-01 Gramineer Internat Ab New method and uses
CA2628265A1 (en) * 2005-11-08 2007-05-18 Multi Formulations Ltd. The use of compositions comprising ketoacids and amino acids for increasing muscle mass and muscle performance
AU2012244748B2 (en) * 2011-04-18 2016-07-14 Nestec S.A. Nutritional compositions comprising alpha-hydroxyisocaproic acid

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6777487A (en) * 1985-12-18 1987-07-15 Veech, R.L. Parenteral nutrition therapy with amino acids
SE8704217D0 (en) * 1987-10-29 1987-10-29 Vinnars Erik Ab AMINO ACID COMPOSITION FOR PARENTERAL NUTRITION

Also Published As

Publication number Publication date
JPH06509362A (en) 1994-10-20
NO306195B1 (en) 1999-10-04
AU661399B2 (en) 1995-07-20
EP0612245A1 (en) 1994-08-31
CA2113279A1 (en) 1993-11-25
AU4098993A (en) 1993-12-13
NO940190L (en) 1994-01-19
WO1993023027A1 (en) 1993-11-25
NO940190D0 (en) 1994-01-19

Similar Documents

Publication Publication Date Title
CA2285203A1 (en) Compositions containing capsaicin or capsaicin analogues and a local anesthetic
LTIP702A (en) A slimming pharmaceutical composition
ES2160704T3 (en) TREATMENT OF THE PARTIAL INSENSIBILITY SYNDROME TO THE GROWTH HORMONE.
ZA885242B (en) Piperazinyl derivatives of purines and isosteres thereof as hypoglycemic agents
GB9517443D0 (en) Increasing creatine and glycogen concentration in muscle
MY109309A (en) Improvements in or relating to somatostatins
SE9201584D0 (en) USE OF ALPHA KETOGLUTARATE
DE3676640D1 (en) PRAZOSINE-PIRBUTEROL MIXTURE FOR BRONCH DILATATION.
Laurence et al. Clinical effects of drugs which prevent the release of adrenergic transmitter
KR890014124A (en) How to Use IL-6 Molecules
SE8802564D0 (en) NEW SYNERGISTIC PREPARATIONS AND A NEW METHOD OF ALLEVIATION OF PAIN
KR900017599A (en) Pharmaceutical composition for tumor treatment
喻明芙 et al. Effects of Hypoxia on Calmodulin Levels of Lung Tissues and Small Pulmonary Arterial Walls in Young Pigs
Serkes et al. Comparison of Normal and Buffered Saline Solution for Fluid Replacement Following Tourniquet Shock.
ATE350026T1 (en) PRESERVATION OF THE BODY&#39;S OWN PROTEINS
TH13496EX (en) Insulin analogues for selective tissue type